Cullinan Oncology (NASDAQ:CGEM) had its target price increased by Morgan Stanley from $38.00 to $40.00 in a research note published on Monday morning, PriceTargets.com reports. Morgan Stanley currently has an equal weight rating on the stock.
A number of other research analysts have also recently issued reports on the company. Evercore ISI began coverage on Cullinan Oncology in a research note on Tuesday, February 2nd. They set an outperform rating and a $55.00 price objective on the stock. SVB Leerink began coverage on Cullinan Oncology in a research note on Tuesday, February 2nd. They issued an outperform rating and a $52.00 target price on the stock. Finally, HC Wainwright raised their target price on Cullinan Oncology from $47.00 to $48.00 and gave the stock a buy rating in a research note on Tuesday, March 30th.
Shares of NASDAQ:CGEM opened at $32.09 on Monday. The company’s 50-day moving average is $41.23. Cullinan Oncology has a 12-month low of $27.01 and a 12-month high of $59.85.
Cullinan Management, Inc, a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer.
Further Reading: Find a Trading Strategy That Works
Receive News & Ratings for Cullinan Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cullinan Oncology and related companies with MarketBeat.com's FREE daily email newsletter.